Table 1 Results of platelet count and... | American Society of Hematology

Table 1

Results of platelet count and IPF values for ITP patient episodes before and up to 10 days after therapeutic interventions

Treatment	Platelet count, × 10⁹/L			Absolute IPF, × 10⁹/L			IPF, %
Treatment	Pretreatment	Maximum posttreatment	Change*	Pretreatment	Maximum posttreatment	Change*	Pretreatment	Maximum posttreatment	Change*
Eltrombopag	13	113	100	7.4	66.4	59‖	57.2	58.8	1.6
Eltrombopag	16	565	549	5.9	29.4	23.5‖	36.6	5.2	−31.4
Eltrombopag	29	173	144	3.4	18.2	14.8‖	11.6	10.5	−1.1
Eltrombopag	2	47	45	1.0	17.4	16.4‖	52.2	37.1	−15.1
Eltrombopag	17	634	617	3.9	23.5	19.6‖	22.8	3.7	−19.1
Placebo†	8	14	6	3.5	4.1	0.6	43.7	29.4	−14.3
GMA161	14	60	46	3.4	13	9.6	24.2	21.6	−2.6
GMA161	13	45	32	1.2	3.8	2.6	9.2	17.1	7.9
Anti-D_X‡	9	79	70	2	5.5	3.5	21.9	6.9	−15
Anti-D_X‡	14	115	101	2.2	2.8	0.6	15.8	2.4	−13.4
Anti-D	13	167	154	2	5	3	15.7	3	−12.7
Anti-D_A§	7	335	328	2.8	8.4	5.6	39.8	2.5	−37.3
Anti-D_A§	10	175	165	2.1	6.8	4.7	21.1	3.9	−17.2
Anti-D	20	163	143	1.8	5.2	3.4	9	3.2	−5.8
Anti-D	16	421	405	2.2	7.6	5.4	14	1.8	−12.2
Anti-D	9	108	99	2.4	5	2.6	26.7	4.6	−22.1
Anti-D	12	409	397	2.5	5.3	2.8	21.2	1.3	−19.9
Anti-D + IVIG	3	160	157	1.8	17.3	15.5‖	60.9	10.8	−50.1
IVIG_Y‡	1	121	120	0.7	33.5	32.8‖	67.2	27.2	−40
IVIG_Y‡	1	79	78	0.3	15.2	14.9‖	26.2	19.2	−7
IVIG_Y‡	1	73	72	0.3	18.4	18.1‖	29.3	25.2	−4.1
IVIG_B§	1	210	209	0.4	12	11.6‖	38.5	5.7	−32.8
IVIG_B§	11	197	186	2.8	16.7	13.9‖	25.8	8.5	−17.3
IVIG	48	113	65	13	17.5	4.5	27	15.5	−11.5
IVIG	10	143	133	1.7	8	6.3	17.3	5.6	−11.7
IVIG	15	58	43	2.1	2.3	0.2	14	4	−10
IVIG	9	46	37	1.7	9.8	8.1	19	21.3	2.3
IVIG	15	159	144	4.3	5.4	1.1	28.9	3.4	−25.5
IVIG	7	171	164	1.5	6.0	4.5	21.3	3.5	−17.8

Treatment	Platelet count, × 10⁹/L			Absolute IPF, × 10⁹/L			IPF, %
Treatment	Pretreatment	Maximum posttreatment	Change*	Pretreatment	Maximum posttreatment	Change*	Pretreatment	Maximum posttreatment	Change*
Eltrombopag	13	113	100	7.4	66.4	59‖	57.2	58.8	1.6
Eltrombopag	16	565	549	5.9	29.4	23.5‖	36.6	5.2	−31.4
Eltrombopag	29	173	144	3.4	18.2	14.8‖	11.6	10.5	−1.1
Eltrombopag	2	47	45	1.0	17.4	16.4‖	52.2	37.1	−15.1
Eltrombopag	17	634	617	3.9	23.5	19.6‖	22.8	3.7	−19.1
Placebo†	8	14	6	3.5	4.1	0.6	43.7	29.4	−14.3
GMA161	14	60	46	3.4	13	9.6	24.2	21.6	−2.6
GMA161	13	45	32	1.2	3.8	2.6	9.2	17.1	7.9
Anti-D_X‡	9	79	70	2	5.5	3.5	21.9	6.9	−15
Anti-D_X‡	14	115	101	2.2	2.8	0.6	15.8	2.4	−13.4
Anti-D	13	167	154	2	5	3	15.7	3	−12.7
Anti-D_A§	7	335	328	2.8	8.4	5.6	39.8	2.5	−37.3
Anti-D_A§	10	175	165	2.1	6.8	4.7	21.1	3.9	−17.2
Anti-D	20	163	143	1.8	5.2	3.4	9	3.2	−5.8
Anti-D	16	421	405	2.2	7.6	5.4	14	1.8	−12.2
Anti-D	9	108	99	2.4	5	2.6	26.7	4.6	−22.1
Anti-D	12	409	397	2.5	5.3	2.8	21.2	1.3	−19.9
Anti-D + IVIG	3	160	157	1.8	17.3	15.5‖	60.9	10.8	−50.1
IVIG_Y‡	1	121	120	0.7	33.5	32.8‖	67.2	27.2	−40
IVIG_Y‡	1	79	78	0.3	15.2	14.9‖	26.2	19.2	−7
IVIG_Y‡	1	73	72	0.3	18.4	18.1‖	29.3	25.2	−4.1
IVIG_B§	1	210	209	0.4	12	11.6‖	38.5	5.7	−32.8
IVIG_B§	11	197	186	2.8	16.7	13.9‖	25.8	8.5	−17.3
IVIG	48	113	65	13	17.5	4.5	27	15.5	−11.5
IVIG	10	143	133	1.7	8	6.3	17.3	5.6	−11.7
IVIG	15	58	43	2.1	2.3	0.2	14	4	−10
IVIG	9	46	37	1.7	9.8	8.1	19	21.3	2.3
IVIG	15	159	144	4.3	5.4	1.1	28.9	3.4	−25.5
IVIG	7	171	164	1.5	6.0	4.5	21.3	3.5	−17.8

The change in the platelet count and IPF indicates the difference between that parameter on the day of treatment and on the day of maximum observed count after treatment.

†

This patient received placebo during the Eltrombopag/placebo randomized controlled study.

‡

Data were available for the same patient on multiple, consecutive treatment episodes with the same agent for patient X with anti-D and patient Y with IVIG.

Data were available for the same patient on multiple, consecutive treatment episodes with the same agent for patient A with anti-D and patient B with IVIG.

‖

Greater than 10 × 10⁹/L increase in absolute IPF.

View Large

This Feature Is Available To Subscribers Only